Assessment of a combination therapy with Candesartan and Celecoxib for patients with advanced hepatocellular carcinoma after transhepatic arterial chemoembolization.

Assessment of a combination therapy with Candesartan and Celecoxib for patients with advanced hepatocellular carcinoma after transhepatic arterial chemoembolization. - Phase 2 randomized trial of a combination therapy with Candesartan and Celecoxib for advanced HCC patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002435

Enrollment

Registered

2009-09-02

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced hepatocellular carcinoma

Interventions

Celecoxib and Candesartan plasebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HCC patients treated with TACE 2) Serum creatinine; less than 1.5 mg/dl, WBC; more than 2000, Total bilirubine; less than 3.0 mg/dl. 3) Performance status; ECOG 0-2 4) Liver damage; Child-Pugh class A or B 5) Patients without any influences of previous treatment.

Exclusion criteria

Exclusion criteria: 1) pregnant woman, patients with severe thrombosis in past 6 months, patients with past history of peptic ulcer. 2) patients less than 120 mmHg of systolic blood pressure

Design outcomes

Primary

Measure	Time frame
Time to progression	—

Secondary

Measure	Time frame
Survival period	—

Countries

Japan

Contacts

Public ContactTakuji Torimura

Kurume University, School of Medicine Department of Medicine, Division of Gastroenterology

tori@med.kurume-u.ac.jp0942-31-7561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026